You can’t say 2016 was a boring year. In addition to highlighting the best and worst for biopharma – the Cures legislation and accelerated regulatory paths, along with the disastrous Bial study and Alzheimer’s disappointments – the year heralded changes in the global political landscape that will begin playing out in 2017.